Luca Arecco: Discussing How Biomarkers Can Optimize Treatment Decisions in Early Breast Cancer at AIOM 2026
Luca Arecco/LinkedIn

Luca Arecco: Discussing How Biomarkers Can Optimize Treatment Decisions in Early Breast Cancer at AIOM 2026

Luca Arecco, Clinical Research Fellow at ESMO, shared on X:

“Grateful for the opportunity to discuss how biomarkers can optimize treatment decisions in early breast cancer during the educational session at the 2026 AIOM national congress.

A great experience shared with an outstanding faculty!

A sincere thanks to all the mentors, colleagues, and friends who have guided me throughout my professional journey!”

Luca Arecco

About AIOM 2026

The XXVIII National Congress of the Italian Association of Medical Oncology (AIOM 2026) took place on November 13-15, 2026, at the Rome Marriott Park Hotel in Rome, Italy. Bringing together medical oncologists, researchers and healthcare professionals, the congress provided a platform for scientific exchange and discussion of advances across the field of oncology.

The 2026 edition was guided by the theme ‘Innovazione Equa’ (Equitable Innovation), emphasizing the importance of ensuring that progress in cancer research, diagnosis and treatment translates into accessible, equitable care, while addressing existing healthcare disparities and preventing new ones.

Organized by the Italian Association of Medical Oncology (AIOM), the congress serves as a key meeting point for the Italian and international oncology community, encouraging collaboration and the integration of scientific innovation into clinical practice.

You can also read: PHERGain Five-Year Results: Chemotherapy-Free HER2-Positive Breast Cancer Treatment Shows Durable Outcomes as ctDNA Refines Risk Assessment

PHERGain